According to a December 10 report from Bloomberg, Elon Musk’s brain-computer interface venture, Neuralink, revealed that it has brought on board David McMullen, the ex-director of the Office of Neurological and Physical Medicine Devices at the U.S. Food and Drug Administration (FDA). This FDA office specifically oversees the regulation of brain-computer implant devices—the very kind Neuralink is developing. McMullen previously played a pivotal role in the approval process for neurological medical device applications, amassing a wealth of expertise in the brain-computer interface domain. Neuralink is at the forefront of crafting brain-computer interface devices designed to facilitate direct communication between the brain and electronic devices. Such technology holds the promise of empowering paralyzed patients to control computers and aiding visually impaired individuals in regaining visual capabilities.